Puma Continues Long Post-ASCO Plunge On Latest Data
This article was originally published in Scrip
Puma Biotechnology Inc.'s data for the tyrosine kinase inhibitor neratinib (PB272) in the treatment of breast cancer now seem to disappoint investors every time the Los Angeles-based company reports results from its clinical trials, bringing Puma's stock to its second-lowest price of the year on Dec. 11.
You may also be interested in...
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.